DexCom, Inc. (NASDAQ:DXCM) Stock Holdings Trimmed by Sit Investment Associates Inc.

Sit Investment Associates Inc. decreased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 2.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 131,243 shares of the medical device company’s stock after selling 3,473 shares during the quarter. Sit Investment Associates Inc.’s holdings in DexCom were worth $10,207,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of DXCM. Katamaran Capital LLP acquired a new position in shares of DexCom in the 4th quarter worth $740,000. Aviva PLC boosted its position in shares of DexCom by 35.9% in the 4th quarter. Aviva PLC now owns 240,902 shares of the medical device company’s stock valued at $18,735,000 after purchasing an additional 63,622 shares during the period. Pilgrim Partners Asia Pte Ltd purchased a new position in DexCom in the 4th quarter worth about $513,000. Resona Asset Management Co. Ltd. acquired a new stake in DexCom during the 4th quarter worth about $9,494,000. Finally, Wealth Advisors of Tampa Bay LLC lifted its stake in DexCom by 14.9% during the fourth quarter. Wealth Advisors of Tampa Bay LLC now owns 17,290 shares of the medical device company’s stock valued at $1,345,000 after buying an additional 2,238 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently commented on DXCM shares. Wells Fargo & Company restated an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Morgan Stanley upped their price target on DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Finally, Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and lifted their target price for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Five research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $99.82.

Insider Transactions at DexCom

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the sale, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, COO Jacob Steven Leach sold 14,076 shares of the firm’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $990,668.88. Following the sale, the chief operating officer now directly owns 313,497 shares in the company, valued at approximately $22,063,918.86. This trade represents a 4.30 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 105,009 shares of company stock valued at $8,044,178. 0.30% of the stock is currently owned by company insiders.

DexCom Stock Down 3.2 %

DexCom stock opened at $59.83 on Friday. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $141.99. The firm has a market capitalization of $23.46 billion, a PE ratio of 41.84, a P/E/G ratio of 2.30 and a beta of 1.50. The company’s 50-day moving average is $80.14 and its 200-day moving average is $76.92. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Sell-side analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.